Clinical trials: Skin Infections (Acne)
- Condition Skin Infections (Acne)
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT06799000
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris II or III Degree, Boils
Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir
To measure the efficacy of Taro Elixir compare with Oxytetracycline in the treatment of boils or acne.
- Trial name
- E01GOU-INH0109 (NCT01032499)
- Testing
- oxytetracycline, taro elixir, Taro Elixir
- Where
- 4 sites in Brazil
- Volunteers
- 120 people
- Sponsor
- Laboratorios Goulart S.A.
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- RECHARGE-2 (NCT06840392)
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 129 sites in United States, Argentina and 17 more
- Volunteers
- 565 people
- Sponsor
- Novartis Pharmaceuticals
Actinic Keratosis, Acne/Rosacea
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders
- Conditions
- Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea
- Trial name
- NCT02759900
- Testing
- Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Skin Center Dermatology Group
Hidradenitis Suppurativa (Acne Inversa)
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to…
- Trial name
- NCT02421172
- Testing
- CJM112
- Where
- 16 sites in United States, Denmark and 3 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
- Trial name
- NCT07213973
- Testing
- Povorcitinib
- Where
- 30 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation